From the perspective of the clinical and pathological characteristics of tumours, the selection criteria could be improved by studying patients presenting similar dissemination patterns or more specific tumour molecular profiles (e.g.: either KRAS positive or negative tumours). Here, KRAS is linked to neoplasm.